乳腺癌肿瘤高甲基化基因1蛋白和透明质酸介导的细胞游走受体表达分析研究

doi:10.16150/j.1671-2870.2017.01.014

诊断学理论与实践 ›› 2017, Vol. 16 ›› Issue (01): 73-78.doi: 10.16150/j.1671-2870.2017.01.014

乳腺癌肿瘤高甲基化基因1蛋白和透明质酸介导的细胞游走受体表达分析研究

吴衍^1,2, 丁佩芬², 顾岩¹, 郭善禹¹, 戴谦诚¹, 张伟¹

1.上海交通大学医学院附属第九人民医院普外科,上海 200011;
2.上海市浦东新区周浦医院普外科,上海 200135

收稿日期:2016-11-10 出版日期:2017-02-25 发布日期:2022-06-20
通讯作者: 张伟 E-mail: weizh1518@hotmail.com
基金资助:
上海市科委自然科学基金（14ZR1424400）; 国家自然科学基金（81572760）

Expression and analysis of HIC-1 and HMMR in breast cancer

WU Yan^1,2, DING Peifen², GU Yan¹, GUO Shanyu¹, DAI Qiancheng¹, ZHANG Wei¹

1. Department of Surgery, Affiliated Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200011, China;
2. Deartment of Surgery, Shanghai Pudong New Area Zhou Pu Hospital,Shanghai 200135, China

Received:2016-11-10 Online:2017-02-25 Published:2022-06-20

摘要/Abstract

摘要： 目的探讨抑癌基因肿瘤高甲基化基因1(hypermethylated in cancer 1, HIC-1)和致癌基因透明质酸介导的细胞游走受体(hyaluronan-mediated motility receptor, HMMR)在乳腺小叶增生、乳腺纤维腺瘤和乳腺癌组织中的表达情况,及其与乳腺癌临床病理参数间的关系。方法应用免疫组织化学方法检测57例患者的乳腺手术切除标本（其中乳腺小叶增生17例,乳腺纤维腺瘤及乳腺癌各20例）中HIC-1与HMMR蛋白的表达情况,观察其染色结果以半定量分析,并结合临床病理学指标进行相关分析。结果 ①乳腺小叶增生和乳腺纤维腺瘤组织中HIC-1蛋白表达呈中度阳性（平均计分均为5.65分）;而乳腺癌组织中HIC-1表达减弱,呈弱阳性（平均计分为2.15分）,二者间差异有统计学意义（P<0.001）。②乳腺小叶增生和纤维腺瘤组织中的HMMR均呈低表达（其中纤维腺瘤平均计分为0.3分,小叶增生平均积分为0）,而乳腺癌组织中HMMR表达呈弱阳性（平均计分为2.3分）,二者间差异有统计学意义（P<0.001）。③ HIC-1 及HMMR蛋白的表达与乳腺癌相关临床病理特征之间未见明显关联。结论抑癌基因HIC-1蛋白在乳腺癌组织中呈明显低表达,而致癌基因HMMR在乳腺癌组织中呈较高表达,HIC-1及受HIC-1调控的下游基因HMMR可能与乳腺恶性肿瘤的发生、发展有关。

关键词: 乳腺癌, 肿瘤高甲基化基因1, 透明质酸介导的细胞游走受体, 免疫组织化学, 临床病理学

Abstract: Objective: To study the expression of tumor suppressor gene hypermethylated in cancer 1(HIC-1)and oncogene hyaluronan-mediated motility receptor (HMMR) in lobular hyperplasia of mammary gland, breast fibroadenoma and breast cancer, as well as their relationship with the clinicopathological parameters of breast cancer. Methods: Expressions of HIC-1 and HMMR was examined by immunohistochemistry on 57 resected tissue samples taken at breast surgery: lobular hyperplasia 17 cases, fibroadenoma 20 cases and breast cancer 20 cases. The staining results were assessed semi-quantitatively, and were analyzed with the clinicopathological parameters of breast cancer. Results: ① HIC-1 was mo-derately positive in lobular hyperplasia and fibroadenoma tissue (average score 5.65), and was weakly positive in breast cancer tissue(average score 2.15). The difference in expression of HIC-1 between mammary benign lesions and breast cancer was significant (P<0.001). ② Expression of HMMR in mammary benign lesions was low (average score of fibroadenoma was 0.3, average score of lobular hyperplasia was 0), while the expression of HMMR in breast cancer was with an average score of 2.3 (P<0.001). ③ No obvious correlation was observed between protein expression of HIC-1 and HMMR and cli-nicopathological parameters of breast cancer. Conclusions: Expression of tumor suppression gene HIC-1 is significantly low and oncogene HMMR is relatively high in breast cancer. HIC-1 and the downstream gene HMMR regulated by HIC-1 may be involved in the development and progress of breast cancer.

Key words: Breast cancer, Hypermethylated in cancer 1, Hyaluronan-mediated motility receptor, Immunohistochemis-try, Clinicopathology

中图分类号:

R737.9

吴衍, 丁佩芬, 顾岩, 郭善禹, 戴谦诚, 张伟. 乳腺癌肿瘤高甲基化基因1蛋白和透明质酸介导的细胞游走受体表达分析研究[J]. 诊断学理论与实践, 2017, 16(01): 73-78.

WU Yan, DING Peifen, GU Yan, GUO Shanyu, DAI Qiancheng, ZHANG Wei. Expression and analysis of HIC-1 and HMMR in breast cancer[J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 73-78.

参考文献

[1] Fan L, Strasser-Weippl K, Li JJ, et al.Breast cancer in China[J]. Lancet Oncol,2014,15(7):e279-e289.
[2] Lu Y, Lin YZ, LaPushin R, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells[J]. Oncogene,1999,18(50):7034-7045.
[3] Fujii H, Biel MA, Zhou W, et al.Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer[J]. Oncogene,1998,16(16):2159-2164.
[4] Kanai Y, Hui AM, Sun L, et al.DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis[J]. Hepatology,1999,29(3):703-709.
[5] Nishida N, Nagasaka T, Nishimura T, et al.Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma[J]. Hepatology,2008,47(3):908-918.
[6] Misra S, Hascall VC, Markwald RR, et al.Interactions between hyaluronan and its receptors(CD44, RHAMM) regulate the activities of inflammation and cancer[J]. Front Immunol,2015,6:201.
[7] 刘雷, 郭磊, 王志威, 等. 新型标志物HAB18G/CD147在大样本胃癌组织中的表达研究[J]. 诊断理论与实践,2012, 11(1):42-46.
[8] 赵峰, 张伟. HIC-1基因在肿瘤发生发展中的作用[J]. 外科理论与实践,2012,17(5):501-504.
[9] Wales MM, Biel MA, el Deiry W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3[J]. Nat Med,1995,1(6):570-577.
[10] Boulay G, Malaquin N, Loison I, et al.Loss of hypermethylated in cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β-2 adrenergic receptor (ADRB2) misregulation[J]. J Biol Chem,2012,287(8):5379-5389.
[11] Nicoll G, Crichton DN, McDowell HE, et al. Expression of the hypermethylated in cancer gene (HIC-1) is associa-ted with good outcome in human breast cancer[J]. Br J Cancer,2001,85(12):1878-1882.
[12] 赵峰, 顾岩, 郭善禹, 等. HIC-1基因在乳腺癌的表达及其对细胞增殖和凋亡的影响[J]. 外科理论与实践,2013, 18(2):159-164.
[13] Zhao F, Pan S, Gu Y, et al.Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer[J]. PLoS One,2014,9(1):e86486.
[14] Entschladen F, Drell TL 4th, Lang K, et al. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters[J]. Lancet Oncol,2004,5(4):254-258.
[15] Woodhouse EC, Chuaqui RF, Liotta LA.General mechanisms of metastasis[J]. Cancer,1997,80(8 Suppl):1529-1537.
[16] Wang C, Thor AD, Moore DH 2nd, et al. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression[J]. Clin Cancer Res,1998,4(3):567-576.
[17] 程晓博, 范莹, 涂巍. CD168与乳腺癌预后的关系[J]. 辽宁大学学报,2013,40(2):185-188.
[18] 马万山, 李晓冰, 汪运山, 等. 胃癌患者原癌基因和抑癌基因的表达谱研究[J]. 肿瘤防治杂志,2002,9(4):379-381.

乳腺癌肿瘤高甲基化基因1蛋白和透明质酸介导的细胞游走受体表达分析研究

Expression and analysis of HIC-1 and HMMR in breast cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王昭晖, 吴海波. 胃神经鞘瘤31例临床病理学分析[J]. 诊断学理论与实践, 2021, 20(06): 552-556.
[2]	李娟, 刘劲松, 李梅, 李殿炜, 朱弘. 细支气管腺瘤10例临床病理分析及文献复习[J]. 诊断学理论与实践, 2021, 20(05): 466-470.
[3]	吴冬梅, 吴丽莉, 陈佳, 刘坤. 淋巴上皮样肝细胞肝癌一例报告附文献复习[J]. 诊断学理论与实践, 2021, 20(05): 498-501.
[4]	侯筱飒, 杨振江. 前哨淋巴结阳性乳腺癌患者发生非前哨淋巴结转移的危险因素分析[J]. 诊断学理论与实践, 2021, 20(03): 284-289.
[5]	陶志远, 史春颖, 张琦, 宋富贵, 吕哲昊. 数字乳腺体层合成在女性青年期乳腺癌筛查中的应用及研究进展[J]. 诊断学理论与实践, 2021, 20(03): 294-297.
[6]	韦若蕖, 余红, 姚志荣. 儿童成纤维细胞结缔组织痣一例报道并文献复习[J]. 诊断学理论与实践, 2021, 20(02): 190-194.
[7]	李芹芹, 金晓龙, 袁菲. 儿童系统性EB病毒阳性T细胞淋巴瘤临床病理分析一例及文献复习[J]. 诊断学理论与实践, 2020, 19(1): 63-68.
[8]	卢叶君, 陈卉, 张剑, 徐斌, 王冲, 贺烨. 超微血管成像、超声弹性成像联合高频超声在微小乳腺癌中的诊断价值及相关高危超声特征的筛选[J]. 诊断学理论与实践, 2020, 19(04): 391-396.
[9]	孟磊俊, 张晶, 王雪莉, 李治, 张泓, 曾乃燕. 儿童伯基特淋巴瘤中差异表达基因的鉴定及临床应用[J]. 诊断学理论与实践, 2020, 19(03): 248-257.
[10]	罗婷, 周建桥. 超声新技术在预测乳腺癌分子标志物中的应用进展[J]. 诊断学理论与实践, 2020, 19(03): 325-328.
[11]	王志威, 张晓晓, 王杰, 魏敏, 邵玉国, 籍敏, 杨莉, 何奇. 局部晚期乳腺癌患者腋窝淋巴结转移范围的影响因素分析[J]. 诊断学理论与实践, 2019, 18(2): 189-192.
[12]	钟明, 赵峰, 吴衍, 裴文江, 高航, 郭善禹, 戴谦诚, 张伟. 血浆游离DNA中抑癌基因肿瘤高甲基化基因1甲基化检测方法的建立及其在乳腺疾病诊断中的意义[J]. 诊断学理论与实践, 2019, 18(2): 144-148.
[13]	何燕燕, 冯砅锦, 蔚青. 前列腺多形性巨细胞腺癌一例报告及文献复习[J]. 诊断学理论与实践, 2019, 18(2): 160-164.
[14]	金娇莺, 李倩玉, 蒋虹伟, 韩冬艳, 奚豪, 蔚青. 混合性嗜铬细胞瘤1例报道并文献复习[J]. 诊断学理论与实践, 2019, 18(2): 165-169.
[15]	王顺利, 邓双双, 高慧, 肖天羽, 高金莉. 乳腺包裹性乳头状癌的临床和病理特征分析[J]. 诊断学理论与实践, 2019, 18(1): 89-92.